At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Losartan Potassiumdrug
Likely dose
Losartan Potassium 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder.
Children's Hospital Medical Center, Cincinnati·interventional·Posted Mar 11, 2013·Updated Sep 24, 2020
In Brief
A Phase 2 clinical trial evaluating Losartan Potassium for Eosinophilic Esophagitis and Connective Tissue Disorders. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The purpose of this research study is to test the safety of losartan potassium and see what effects (good and bad) it has on you and your eosinophilic esophagitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 2013
Enrollment StartOct 2013
Primary CompletionJan 2015
Study CompletionFeb 2015
TodayJul 2026
First PostedMar 11, 2013
Enrollment StartOct 10, 2013
Primary CompletionJan 13, 2015
Study CompletionFeb 13, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.3 years ago
Interventions
Losartan Potassiumdrug
The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.